← feed

Is NCT02642016 results overdue?

Yes — results are overdue. Primary completion was 2018-01-30; the FDAAA-801 reporting deadline (2019-01-30) passed 2699 days ago and no results are posted on ClinicalTrials.gov.

A Study to Evaluate the Safety and Pharmacokinetics of CDX-0158 in Adult Patients With Advanced Solid Tumors

NCT IDNCT02642016 ↗
SponsorCelldex Therapeutics (INDUSTRY)
Public issuerCelldex Therapeutics, Inc. — CLDX (CIK 0000744218) best-effort name match, 95% conf — verify on EDGAR ↗
PhasePHASE1
StatusCOMPLETED
Primary completion2018-01-30 (ACTUAL)
Reporting deadline2019-01-30 (completion + 365d)
Days overdue2699
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 9f5c9c80ac14be2d… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT02642016. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →